PRESS RELEASE
PledPharma AB

Information on the Annual General Meeting and Covid-19

Stockholm, April 2, 2020. PledPharma AB (STO: PLED) has decided to take a number of preventive measures before the annual general meeting to minimize the risk of spreading the new corona virus Covid-19.

The goal for the AGM is to be short and efficient with the least risk of spreading the infection. This can for example result in shortened introduction and presentations. Coffee and sweets will neither be served in conjunction with the AGM.

PledPharma reminds shareholders about the possibility of not attending the AGM in person. Shareholders can instead use the possibility of voting through a proxy. Shareholders that are ill, have symptoms of the disease, been visiting infectious disease risk areas or belong to a risk group should participate through a proxy. A proxy form for representatives is available on the Company's website www.pledpharma.se.

PledPharma closely monitors the development of the spread of infection and the authorities' directives and publishes updated information on the company's website www.pledpharma.se if necessary.

For further information, please contact:
Yilmaz Mahshid, CFO
Tel. +46 (0)72 231 68 00
yilmaz.mahshid@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project **PledOx**® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate **Aladote**® is being developed to reduce the risk of acute liver injury associated with paracetamol/acetaminophen poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market. For more information, see http://www.pledpharma.com/